These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 28216404)
1. Discovery of novel substituted octahydropyrrolo[3,4-c]pyrroles as dual orexin receptor antagonists for insomnia treatment. Wu S; Sun Y; Hu Y; Zhang H; Hou L; Liu X; Li Y; He H; Luo Z; Chen Y; Wang Y; Shi W; Shen L; Cao C; Liang W; Xu Q; Lv Q; Lan J; Li J; Chen S Bioorg Med Chem Lett; 2017 Mar; 27(6):1458-1462. PubMed ID: 28216404 [TBL] [Abstract][Full Text] [Related]
2. Novel Octahydropyrrolo[3,4-c]pyrroles Are Selective Orexin-2 Antagonists: SAR Leading to a Clinical Candidate. Letavic MA; Bonaventure P; Carruthers NI; Dugovic C; Koudriakova T; Lord B; Lovenberg TW; Ly KS; Mani NS; Nepomuceno D; Pippel DJ; Rizzolio M; Shelton JE; Shah CR; Shireman BT; Young LK; Yun S J Med Chem; 2015 Jul; 58(14):5620-36. PubMed ID: 26087021 [TBL] [Abstract][Full Text] [Related]
3. [Preclinical and clinical results of dual orexin receptor antagonist, suvorexant (BELSOMRA(®)), a novel therapeutic agent for insomnia]. Tanaka Y; Aoki I; Ishine T; Renger JJ; Winrow CJ; Hisada S Nihon Yakurigaku Zasshi; 2016 Jul; 148(1):46-56. PubMed ID: 27430679 [No Abstract] [Full Text] [Related]
4. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia. Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547 [TBL] [Abstract][Full Text] [Related]
5. Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements. Roecker AJ; Mercer SP; Bergman JM; Gilbert KF; Kuduk SD; Harrell CM; Garson SL; Fox SV; Gotter AL; Tannenbaum PL; Prueksaritanont T; Cabalu TD; Cui D; Lemaire W; Winrow CJ; Renger JJ; Coleman PJ Bioorg Med Chem Lett; 2015 Nov; 25(21):4992-4999. PubMed ID: 25613676 [TBL] [Abstract][Full Text] [Related]
6. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. Roecker AJ; Cox CD; Coleman PJ J Med Chem; 2016 Jan; 59(2):504-30. PubMed ID: 26317591 [TBL] [Abstract][Full Text] [Related]
7. Discovery of Highly Potent Dual Orexin Receptor Antagonists via a Scaffold-Hopping Approach. Heidmann B; Gatfield J; Roch C; Treiber A; Tortoioli S; Brotschi C; Williams JT; Bolli MH; Abele S; Sifferlen T; Jenck F; Boss C ChemMedChem; 2016 Oct; 11(19):2132-2146. PubMed ID: 27390287 [TBL] [Abstract][Full Text] [Related]
9. The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders. Boss C; Gatfield J; Brotschi C; Heidmann B; Sifferlen T; von Raumer M; Schmidt G; Williams JT; Treiber A; Roch C ChemMedChem; 2020 Dec; 15(23):2286-2305. PubMed ID: 32937014 [TBL] [Abstract][Full Text] [Related]
13. Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Roecker AJ; Reger TS; Mattern MC; Mercer SP; Bergman JM; Schreier JD; Cube RV; Cox CD; Li D; Lemaire W; Bruno JG; Harrell CM; Garson SL; Gotter AL; Fox SV; Stevens J; Tannenbaum PL; Prueksaritanont T; Cabalu TD; Cui D; Stellabott J; Hartman GD; Young SD; Winrow CJ; Renger JJ; Coleman PJ Bioorg Med Chem Lett; 2014 Oct; 24(20):4884-90. PubMed ID: 25248679 [TBL] [Abstract][Full Text] [Related]
14. Orexin Receptor Antagonists: Historical Perspectives and Future Opportunities. Andrews SP; Aves SJ; Christopher JA; Nonoo R Curr Top Med Chem; 2016; 16(29):3438-3469. PubMed ID: 26416477 [TBL] [Abstract][Full Text] [Related]
15. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. Herring WJ; Roth T; Krystal AD; Michelson D J Sleep Res; 2019 Apr; 28(2):e12782. PubMed ID: 30338596 [TBL] [Abstract][Full Text] [Related]
16. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation. Beuckmann CT; Ueno T; Nakagawa M; Suzuki M; Akasofu S Sleep; 2019 Jun; 42(6):. PubMed ID: 30923834 [TBL] [Abstract][Full Text] [Related]
17. Orexin Receptor Antagonists and Insomnia. Wu X; Xue T; Chen Z; Wang Z; Chen G Curr Psychiatry Rep; 2022 Oct; 24(10):509-521. PubMed ID: 35972717 [TBL] [Abstract][Full Text] [Related]
18. Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia. Owen RT Drugs Today (Barc); 2016 Jan; 52(1):29-40. PubMed ID: 26937493 [TBL] [Abstract][Full Text] [Related]
19. Effect of 1-substitution on tetrahydroisoquinolines as selective antagonists for the orexin-1 receptor. Perrey DA; German NA; Decker AM; Thorn D; Li JX; Gilmour BP; Thomas BF; Harris DL; Runyon SP; Zhang Y ACS Chem Neurosci; 2015 Apr; 6(4):599-614. PubMed ID: 25643283 [TBL] [Abstract][Full Text] [Related]
20. Discovery of 5''-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2':5',3''-terpyridine-3'-carboxamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Roecker AJ; Mercer SP; Schreier JD; Cox CD; Fraley ME; Steen JT; Lemaire W; Bruno JG; Harrell CM; Garson SL; Gotter AL; Fox SV; Stevens J; Tannenbaum PL; Prueksaritanont T; Cabalu TD; Cui D; Stellabott J; Hartman GD; Young SD; Winrow CJ; Renger JJ; Coleman PJ ChemMedChem; 2014 Feb; 9(2):311-22. PubMed ID: 24376006 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]